Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development
The novel coronavirus SARS-CoV-2 emerged in China in 2019 and quickly spread globally, causing a pandemic. There is an urgent need to develop vaccines against the virus, and both convalescent plasma and immune globulin are currently in clinical trials for treatment of patients with COVID-19. It is u...
| Auteurs principaux: | , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Taylor & Francis Group
2021-01-01
|
| Collection: | Human Vaccines & Immunotherapeutics |
| Sujets: | |
| Accès en ligne: | http://dx.doi.org/10.1080/21645515.2020.1787074 |